Semaglutide
Semaglutide
Metabolic & Endocrine
Semaglutide is indexed as peptide in the PeptideBase article library. It is referenced in “CagriSema Explained: Semaglutide, Cagrilintide, and the Amylin + GLP-1 Strategy” and 14 other PeptideBase articles. This page groups the relevant coverage; evidence strength, safety, and clinical relevance depend on the specific claim and source.
Deep Dives on Semaglutide
Start here for the plain-English articles connected to this peptide.
Does Semaglutide Raise Pancreatic Cancer Risk? What the Nordic Registry Study Can—and Cannot—Rule Out
A Nordic registry study found no increased pancreatic cancer signal among semaglutide initiators with type 2 diabetes, but short follow-up and conference-only reporting limit what it can rule out.
Read articleDoes Semaglutide Protect the Heart Beyond Weight Loss? What the SELECT Mediation Analysis Shows
SELECT showed fewer major cardiovascular events with semaglutide. A 2026 mediation analysis found that measured weight and risk-factor changes explained only part of the result, without proving a direct heart mechanism.
Read articleDid Semaglutide Extend Lifespan? What the Female-Mouse Ageing Study Actually Shows
A 2026 Nature study found longer median lifespan in older female mice given semaglutide, but separate cohorts, reduced food intake and animal-only evidence sharply limit the human claim.
Read articleFDA Warned Four Peptide Sellers at Once: What the September 2026 Letters Actually Say
FDA's four September 2026 peptide seller warning letters show why research-only disclaimers did not outweigh human-drug claims, bacteriostatic water, guides, calculators, and other injection-related sales context.
Read articleGLP-1 Drugs and Gastroparesis: What 13 Published Cases Can—and Cannot—Show
A 2026 systematic review found only 12 case reports describing 13 patients. Here is what that GLP-1 gastroparesis evidence signals—and why it cannot establish incidence, causality, or comparative drug risk.
Read articleDo GLP-1 Drugs Increase Bowel Obstruction Risk? What a 298,124-Person Study Found
A nationwide Japanese study found no increased one-year risk of serious bowel obstruction or ileus after GLP-1 receptor-agonist initiation versus SGLT2-inhibitor initiation, but important limits remain.
Read articleGLP-1 Weight Loss and AgRP Neurons: What the New Female-Mouse Study Actually Shows
A 2026 PNAS study found that intact AgRP neuron circuitry was needed for the full weight-lowering response to GLP-1 receptor agonists in female mice. Here is what that causal result means—and what it cannot establish in humans.
Read articleTE-8105: What a 38-Person First-in-Human Long-Acting GLP-1 Trial Actually Shows
TE-8105 had an approximately 120-hour half-life in a 38-person open-label Phase 1 study. Here is what that finding—and the early weight and safety observations—can and cannot establish.
Read articleCan Adults Safely Use Grey-Market Semaglutide? What a 20-Person Simulation Actually Shows
What a 20-person simulation reveals about grey market semaglutide safety, self-injection process errors, confidence, product uncertainty, and study limitations.
Read articleDo GLP-1 Drugs Cause Hair Loss? What the New BMJ Study Actually Shows
A 2026 BMJ target-trial emulation found a low-frequency association between GLP-1 receptor agonists and non-scarring alopecia in adults with type 2 diabetes, but it did not prove causation.
Read articlePeptides for Long COVID: What Is Being Studied—and What Is Only Being Marketed
No peptide is proven to treat Long COVID. Separate controlled trials of tirzepatide and larazotide from planned research, animal studies, anecdotes, and marketing.
Read articleGLP-1 Side Effects: What Trials, Labels, and Online Communities Can Each Tell Us
GLP-1 side-effect claims mean different things depending on whether they come from clinical trials, FDA labels, adverse-event databases, or online communities. This evidence-method guide explains how to read each source without turning anecdotes into proof or labels into panic.
Read articleIs Orforglipron a Peptide? The New Oral GLP-1 Pill Explained
Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist. This clarifier explains why people confuse it with peptide GLP-1 drugs and how FDA-approved Foundayo differs from research peptides.
Read articleCagriSema Explained: Semaglutide, Cagrilintide, and the Amylin + GLP-1 Strategy
A cautious, evidence-aware explainer on CagriSema, the investigational semaglutide plus cagrilintide combination, and why the amylin + GLP-1 strategy is not just stronger semaglutide.
Read articleGLP-1 Peptides vs “Research Peptides”: What People Mean and Why It Matters
A clear, evidence-aware guide to why GLP-1 drugs are peptides, how semaglutide and tirzepatide differ from vague research-peptide marketing, and why regulatory status matters.
Read articleQuick Facts
- Origin
- Named peptide referenced in PeptideBase coverage
- Category
- Metabolic & Endocrine